An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (Mpro) of SARS-COV-2 from crude natural extractsArticle Published on 2023-01-152022-11-15 Journal: Talanta [Category] SARS, 유전자 메커니즘, 치료제, [키워드] Analysis applied approach baicalein binding carried catalytic characteristic Chinese complementary complex Compound Covalent binder Cys145 database drug target electrophilic Final functional HIS163 HIS164 His41 independent inhibitor inhibitors Ion knowledge M pro M(pro) mass mass spectrometry maturation metabolomic metabolomics Michael molecular dynamics MPro nucleophilic peptide platform polyprotein protease protein-ligand Proteins proteomic proteomics residue SARS-CoV-2 SARS-CoV-2. Scutellaria baicalensis tested the SARS-CoV-2 [DOI] 10.1016/j.talanta.2022.123824 PMC 바로가기
Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasiaArticle Published on 2022-11-072022-11-16 Journal: Orphanet Journal of Rare Diseases [Category] 유전자 메커니즘, [키워드] analysis Angiogenesis assigned Biomarkers bleeding Blood center double-blind doxycycline Effectiveness ENG Epistaxis Frequency heart failure help hemorrhage Hemorrhagic Hereditary Hereditary hemorrhagic telangiectasia Hereditary hemorrhagic telangiectasia. HHT IL-6 Inflammatory intravenous limitations Liver disease malformation marker mechanism Michael morbidity no significant difference not significantly different observation pathway Patient Placebo placebo-controlled provided Quality of life Randomized controlled trial Randomly RBC recruited Registered Registration secondary significantly higher stroke telangiectasia therapy Toronto Treatment treatment period Trial VEGF [DOI] 10.1186/s13023-022-02539-8 PMC 바로가기
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccinesBNT162b2 및 CoronaVac 백신으로 회복된 COVID-19 환자 중 Omicron 변이체에 대한 혈청 중화 활성 증가Article Published on 2022-05-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Analysis Antibody test Beta Beta variant BNT162b2 characteristic CoronaVac country COVID-19 Cutoff Delta delta variant detectable determine dose evade geometric geometric mean greater Immunity Inactivated vaccine individual induce Infection Live virus Michael mRNA vaccine mRNA vaccine. NAb titer Neutralizing activity neutralizing antibody of BNT162b2 omicron Omicron variant prospective cohort study Protein receiver receiver operating characteristic Receptor binding recipient recovered COVID-19 patient Recovered COVID-19 patients Reinfection Richard risk SARS-CoV-2 Sensitivity and specificity seropositive serum Serum neutralizing antibody significantly higher spike Spike protein Spike protein receptor binding domain statistically subgroup analysis surrogate Surrogate neutralizing antibody test vaccination Vaccine variant variants virus with COVID-19 [DOI] 10.1016/j.ebiom.2022.103986 PMC 바로가기 [Article Type] Article
In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent DockingSilico 약물 재배치에서 SARS-COV-2 주 프로테아제를 표적화하여 약물 코어 모델 및 공유 도킹의 결합 된 구조 기반 가상 스크리닝 전략을 사용하는 공유 억제제로서Article Published on 2022-04-032022-08-31 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] Adding affinity appearance Bicalutamide caused Cimetidine cleavage CMX-2043 Combined complex conserved coronavirus covalent binding covalent inhibitors Cys145 cysteine docking drug drug repositioning DrugBank drugs effective Efficacy Efficiency electrophilic energy contribution energy contributions Epidemic FDA FDA-approved drug FDA-approved drugs identify inhibitor inhibitor N3 inhibitors inhibitors of SARS-CoV-2 Interaction Ixazomib limit M pro mechanism Michael Model molecular MPro pharmacophore pharmacophore modeling Probability protease proteinase provided Replication repositioning required SARS-CoV-2 SARS-CoV-2 coronavirus SARS-CoV-2 Mpro Scopolamine Screening Spread Strategy structure-based virtual screening. target the SARS-CoV-2 therapeutic target Treatment Vaborbactam Vaccines variety Viral viral variant Viral variants Virtual screening [DOI] 10.3390/ijms23073987 PMC 바로가기 [Article Type] Article
Research on Health Disparities Related to the COVID-19 Pandemic: A Bibliometric AnalysisArticle Published on 2022-01-222022-10-29 Journal: International Journal of Environmental Research an [Category] COVID-19, SARS, [키워드] Analysis articles authors bibliometric analysis contributed coronavirus COVID-19 database disparity distribution Factor Factors Features Health Health disparities Health inequalities include Intervention issue journal knowledge Marmot mental health Michael organizations outbreak pandemic provide Public public health public health emergency public health regulatory policy Racial Regulatory Research retrieved Support the United State Topic [DOI] 10.3390/ijerph19031220 PMC 바로가기 [Article Type] Article
Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank경증에서 중등도의 Covid-19 환자의 치료에서 Bucillamine : Michael Frank와의 인터뷰Interview Published on 2022-01-192022-08-31 Journal: Future Microbiology [Category] MERS, 신약개발, 임상, [키워드] Anti-inflammatory bucillamine clinical trial COVID-19 COVID-19 therapeutics Frank Michael Mild moderate Patient SARS-CoV-2 Treatment [DOI] 10.2217/fmb-2021-0277 PMC 바로가기 [Article Type] Interview
Discussion on “Improving precision and power in randomized trials for COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes” by David Benkeser, Ivan Diaz, Alex Luedtke, Jodi Segal, Daniel Scharfstein, and Michael RosenblumDavid Benkeser, Ivan Diaz, Alex Luedtke, Jodi Segal, Daniel Scharfstein 및 Michael의 "공변량 조정을 사용하여 이항, 순서 및 이벤트 발생 시간 결과에 대한 COVID-19 치료에 대한 무작위 시험의 정밀도 및 검정력 향상"에 대한 토론 로젠블룸Comment Published on 2021-12-012022-09-11 Journal: Biometrics [Category] SARS, 임상, [키워드] Alex covariate adjustment COVID-19 treatment Daniel DAVID Michael Precision randomized trial Segal [DOI] 10.1111/biom.13494 PMC 바로가기 [Article Type] Comment
Cash transfer during the COVID-19 pandemic: a multicentre, randomised controlled trialRandomized Controlled Trial Published on 2021-12-012022-10-05 Journal: Family medicine and community health [Category] SARS, 임상, [키워드] 95% CI benefit Cash clinical criteria close contact COVID-19 COVID-19 symptom determine did not reduce Effect evaluate the effect group Health health equity IMPROVE individual Manitoulin Island Michael multicentre not differ number of symptom outcome participant physical distancing physically preventive medicine. primary care Primary outcome random randomised randomised controlled trial reported risk SARS-CoV-2 secondary secondary outcome statistically significant Support Toronto transfer Trial with COVID-19 [DOI] 10.1136/fmch-2021-001452 PMC 바로가기 [Article Type] Randomized Controlled Trial
412. Estimating the Impact of School Classroom Sizes on the Probability of Severe Acute Respiratory Syndrome Coronavirus-2 Infectivity or ExposurePoster Abstracts Published on 2021-11-042022-10-29 Journal: Open Forum Infectious Diseases [Category] COVID-19, [키워드] acute respiratory syndrome age average calculated classroom Cohort Community compartmental model confirmed COVID-19 case Contact Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 case COVID-19 infection COVID-19 transmission Enrollment estimate event exposure follow-up period group Impact increase in Infection Infectivity Isolation Michael Mitigation North Pfizer Prevalence prevalence rates quarantine reducing Reproduction number respiratory Result risk of COVID-19 Safe School Schools SEIR Smith susceptible the United State Total Transmission [DOI] 10.1093/ofid/ofab466.613 PMC 바로가기 [Article Type] Poster Abstracts
The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serumSARS-CoV-2 회복기 혈청의 중화 활성 및 RBD 결합에 대한 스파이크 N501Y 돌연변이의 영향Article Published on 2021-09-012022-09-11 Journal: EBioMedicine [Category] MERS, SARS, 변종, 진단, [키워드] 95% CI Amino acid amino acids ANOVA Anti-RBD IgG Anti-S1 antibody Antibody binding assays B.1.1.7 B.1.351 binding binding domain clinician collected convalescent sera convalescent serum COVID-19 COVID-19 patient determine enzyme immunoassay evaluated geometric geometric mean geometric mean titer GMT Hong Kong IgG isolates K417N Lineage mean difference Michael microneutralization N501Y N501Y mutation neutralization Neutralizing activity neutralizing antibody Neutralizing antibody Spike protein receptor binding domain NSP2 one-way ANOVA Patient positive Protein RBD RBD binding Receptor binding Receptor binding domain recovered COVID-19 patient reduced Richard SARS-CoV-2 SARS-CoV-2 isolate SARS-CoV-2 lineage SARS-CoV-2 N501Y variant B.1.1.7 sensitivity sera serum service significantly spike Spike protein Spike receptor binding domain Spread statistically susceptibility symptom onset tested variant variants virus virus variant virus variants viruses VoC VOC. was determined wild-type [DOI] 10.1016/j.ebiom.2021.103544 PMC 바로가기 [Article Type] Article